JimmyJohannesMD

Clinical Trials

• Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults Start of enrollment: 2018 Oct 10

  Completed

  Phase 2

• A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) Start of enrollment: 2018 Jun 15

  Completed

  Phase 3

• A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) Start of enrollment: 2018 Aug 03

  Completed

  Phase 3

• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy Start of enrollment: 2018 Oct 09

  Completed

  Phase 3

• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) Start of enrollment: 2019 Aug 28

  Completed

  Phase 3

• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy Start of enrollment: 2019 Dec 05

  Completed

  Phase 3

• A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele Start of enrollment: 2019 Nov 25

  Completed

  Phase 2

• Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis Start of enrollment: 2020 Jul 03

  Completed

  Phase 1

• Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 Start of enrollment: 2020 Jun 16

  Terminated

  Phase 3

• Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 Start of enrollment: 2020 Jun 10

  Completed

  Phase 1, Phase 2

• A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) Start of enrollment: 2023 Feb 27

  Recruiting

  Phase 1, Phase 2

• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) Start of enrollment: 2021 Sep 14

  Completed

  Phase 3

• Phase 1 Study to Assess Safety and Efficacy of ANG003 Start of enrollment: 2023 Aug 25

  Recruiting

  Phase 1

• Join now to see all